Clinical trials: Myasthenic Syndrome
Lambert Eaton Myasthenic Syndrome
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
- Trial name
- NCT01377922
- Testing
- Amifampridine Phosphate
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 38 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Lambert-Eaton Myasthenic Syndrome
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during…
- Trial name
- NCT02970162
- Testing
- Amifampridine Phosphate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Muscle Weakness
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome.
- Trial name
- 3-4DAP (NCT02090725)
- Testing
- 3-4 Diaminopyridine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jeffrey A. Cohen, MD
Myasthenic Syndromes, Congenital
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain…
- Trial name
- NCT02562066
- Testing
- amifampridine phosphate
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
- Trial name
- DAPPER (NCT01511978)
- Testing
- Continuous 3,4-DAP
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jacobus Pharmaceutical